{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=34",
    "query": {
      "condition": "Skin Condition",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 16278,
    "total_pages": 1628,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T11:18:24.826Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02595008",
      "title": "Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "DSXS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-08-28",
      "completion_date": "2017-08-25",
      "has_results": true,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595008"
    },
    {
      "nct_id": "NCT00002417",
      "title": "A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Amprenavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glaxo Wellcome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 1,
      "location_summary": "Research Triangle Park, North Carolina",
      "locations": [
        {
          "city": "Research Triangle Park",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002417"
    },
    {
      "nct_id": "NCT02677389",
      "title": "Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer Survivor",
        "Healthy Subject",
        "Stage I Colorectal Cancer",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIA Colorectal Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIB Colorectal Cancer",
        "Stage IIC Colorectal Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Colorectal Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Colorectal Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IIIC Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Monitoring Device",
          "type": "DEVICE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-07-01",
      "completion_date": "2018-01-24",
      "has_results": false,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02677389"
    },
    {
      "nct_id": "NCT05108558",
      "title": "Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peyronie's Disease"
      ],
      "interventions": [
        {
          "name": "CCH administration",
          "type": "DRUG"
        },
        {
          "name": "Control - Crossover to CCH",
          "type": "DRUG"
        },
        {
          "name": "RestoreX",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Charitable Union for the Research and Education of Peyronie's Disease",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2021-09-20",
      "completion_date": "2026-06-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 1,
      "location_summary": "Orem, Utah",
      "locations": [
        {
          "city": "Orem",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05108558"
    },
    {
      "nct_id": "NCT00324155",
      "title": "Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 681,
      "start_date": "2006-08",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-03",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 32,
      "location_summary": "Anaheim, California • La Verne, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324155"
    },
    {
      "nct_id": "NCT06329843",
      "title": "Intermountain Inpatient Bilirubin Decision Accuracy Study Using Smartphone-based Measurements by Picterus Jaundice Pro",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neonatal Jaundice"
      ],
      "interventions": [
        {
          "name": "Picterus Jaundice Pro (JP)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Picterus AS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Hours",
        "maximum_age": "192 Hours",
        "sex": "ALL",
        "summary": "12 Hours to 192 Hours"
      },
      "enrollment_count": 500,
      "start_date": "2024-02-12",
      "completion_date": "2024-05",
      "has_results": false,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06329843"
    },
    {
      "nct_id": "NCT02605915",
      "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-Positive Metastatic Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Locally Advanced or Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2015-12-31",
      "completion_date": "2019-11-13",
      "has_results": false,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605915"
    },
    {
      "nct_id": "NCT02300935",
      "title": "Study of Trametinib and Nab-paclitaxel in Patients With Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-12",
      "completion_date": "2016-01-20",
      "has_results": false,
      "last_update_posted_date": "2019-05-30",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02300935"
    },
    {
      "nct_id": "NCT01106235",
      "title": "Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-12-21",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106235"
    },
    {
      "nct_id": "NCT05892068",
      "title": "A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Tucatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2023-05-09",
      "completion_date": "2028-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-26T11:18:24.826Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05892068"
    }
  ]
}